The impact of carbohydrate restriction-induced elevations in low-density lipoprotein cholesterol on progression of coronary atherosclerosis: the ketogenic diet trial study design
- PMID: 38861193
- PMCID: PMC11426984
- DOI: 10.1097/MCA.0000000000001395
The impact of carbohydrate restriction-induced elevations in low-density lipoprotein cholesterol on progression of coronary atherosclerosis: the ketogenic diet trial study design
Abstract
Background: Despite innovations in pharmacotherapy to lower lipoprotein cholesterol and apolipoprotein B, risk factors for atherosclerotic cardiovascular disease (ASCVD), ASCVD persists as the leading global cause of mortality. Elevations in low-density lipoprotein cholesterol (LDL-C) are a well-known risk factor and have been a main target in the treatment of ASCVD. The latest research suggests that ketogenic diets are effective at improving most non-LDL-C/apolipoprotein B cardiometabolic risk factors. However, ketogenic diets can induce large increases in LDL-C to >190 mg/dl in some individuals. Interestingly, these individuals are often otherwise lean and healthy. The influence of increased levels of LDL-C resulting from a carbohydrate-restricted ketogenic diet on the progression of atherosclerosis in otherwise metabolically healthy individuals is poorly understood. This observational study aims to assess and describe the progression of coronary atherosclerosis in this population within 12 months.
Methods: Hundred relatively lean individuals who adopted ketogenic diets and subsequently exhibited hypercholesterolemia with LDL-C to >190 mg/dl, in association with otherwise good metabolic health markers, were enrolled and observed over a period of 12 months. Participants underwent serial coronary computed tomography angiography scans to assess the progression of coronary atherosclerosis in a year.
Results: Data analysis shall begin following the conclusion of the trial with results to follow.
Conclusion: Ketogenic diets have generated debate and raised concerns within the medical community, especially in the subset exhibiting immense elevations in LDL-C, who interestingly are lean and healthy. The relationship between elevated LDL-C and ASCVD progression in this population will provide better insight into the effects of diet-induced hypercholesterolemia.
Copyright © 2024 The Author(s). Published by Wolters Kluwer Health, Inc.
Conflict of interest statement
There are no conflicts of interest.
Figures
Similar articles
-
Low-Density Lipoprotein Cholesterol Lowering for the Primary Prevention of Cardiovascular Disease Among Men With Primary Elevations of Low-Density Lipoprotein Cholesterol Levels of 190 mg/dL or Above: Analyses From the WOSCOPS (West of Scotland Coronary Prevention Study) 5-Year Randomized Trial and 20-Year Observational Follow-Up.Circulation. 2017 Nov 14;136(20):1878-1891. doi: 10.1161/CIRCULATIONAHA.117.027966. Epub 2017 Sep 6. Circulation. 2017. PMID: 28877913 Clinical Trial.
-
Longitudinal Data From the KETO-CTA Study: Plaque Predicts Plaque, ApoB Does Not.JACC Adv. 2025 Jul;4(7):101686. doi: 10.1016/j.jacadv.2025.101686. Epub 2025 Apr 7. JACC Adv. 2025. PMID: 40192608
-
Genetically predicted lipoprotein(a) associates with coronary artery plaque severity independent of low-density lipoprotein cholesterol.Eur J Prev Cardiol. 2025 Jan 27;32(2):116-127. doi: 10.1093/eurjpc/zwae271. Eur J Prev Cardiol. 2025. PMID: 39158116 Free PMC article.
-
Ketogenic diet and other dietary treatments for epilepsy.Cochrane Database Syst Rev. 2016 Feb 9;2:CD001903. doi: 10.1002/14651858.CD001903.pub3. Cochrane Database Syst Rev. 2016. Update in: Cochrane Database Syst Rev. 2018 Nov 07;11:CD001903. doi: 10.1002/14651858.CD001903.pub4. PMID: 26859528 Updated.
-
Ketogenic diet and other dietary treatments for epilepsy.Cochrane Database Syst Rev. 2012 Mar 14;(3):CD001903. doi: 10.1002/14651858.CD001903.pub2. Cochrane Database Syst Rev. 2012. Update in: Cochrane Database Syst Rev. 2016 Feb 09;2:CD001903. doi: 10.1002/14651858.CD001903.pub3. PMID: 22419282 Updated.
Cited by
-
The Ketogenic Diet in Obesity Management: Friend or Foe?Cell Biochem Biophys. 2025 Aug 29. doi: 10.1007/s12013-025-01878-0. Online ahead of print. Cell Biochem Biophys. 2025. PMID: 40879882 Review.
References
-
- Libby P. The changing landscape of atherosclerosis. Nature 2021; 592:524–533. - PubMed
-
- Kohli-Lynch CN, Thanassoulis G, Moran AE, Sniderman AD. The clinical utility of apoB versus LDL-C/non-HDL-C. Clin Chim Acta 2020; 508:103–108. - PubMed
-
- Wang N, Woodward M, Huffman MD, Rodgers A. Compounding benefits of cholesterol-lowering therapy for the reduction of major cardiovascular events: systematic review and meta-analysis. Circ Cardiovasc Qual Outcomes 2022; 15: e008552. - PubMed
-
- Araújo J, Cai J, Stevens J. Prevalence of optimal metabolic health in American adults: National Health and Nutrition Examination Survey 2009–2016. Metab Syndr Relat Disord 2019; 17:46–52. - PubMed